ATTO · Attovia Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Frazier Life Sciences XI, L.P. | ▲ Buy | Open Market | 6,154,213 Shares held | 8/6/2026 | View profile |
| venBio Global Strategic Fund IV, L.P. | ▲ Buy | Open Market | 4,181,367 Shares held | 8/6/2026 | View profile |
| WALSH COLIN Director | ▲ Buy | Open Market | 3,020,632 Shares held | 8/6/2026 | View profile |
| Deep Track Biotechnology Master Fund, Ltd. | ▼ Sell | Other | 1,957,138 Shares held | 8/6/2026 | View profile |
| Redmile Group, LLC 10% Owner | ▲ Buy | Open Market | 1,182,854 Shares held | 8/6/2026 | View profile |
Transaction History
| WALSH COLIN | ▲ Buy | Open Market | 500,000 | $8.5M | 8/6/2026 |
| venBio Global Strategic Fund IV, L.P. | ▼ Sell | Other | 2,311,870 | — | 8/6/2026 |
| Frazier Life Sciences XI, L.P. | ▼ Sell | Other | 1,749,192 | — | 8/6/2026 |
| Frazier Life Sciences XI, L.P. | ▼ Sell | Other | 961,322 | — | 8/6/2026 |
| WALSH COLIN | ▼ Sell | Other | 478,498 | $0 | 8/6/2026 |
| venBio Global Strategic Fund IV, L.P. | ▲ Buy | Open Market | 382,352 | $6.5M | 8/6/2026 |
| Redmile Group, LLC | ▲ Buy | Open Market | 400,000 | $6.8M | 8/6/2026 |
| Frazier Life Sciences XI, L.P. | ▼ Sell | Other | 1,590,175 | — | 8/6/2026 |
| Frazier Life Sciences XI, L.P. | ▼ Sell | Other | 1,189,940 | — | 8/6/2026 |
| Frazier Life Sciences XI, L.P. | ▲ Buy | Open Market | 588,235 | $10.0M | 8/6/2026 |
| Redmile Group, LLC | ▲ Buy | Open Market | 200,000 | $3.4M | 8/6/2026 |
| Redmile Group, LLC | ▼ Sell | Other | 782,854 | — | 8/6/2026 |
| venBio Global Strategic Fund IV, L.P. | ▼ Sell | Other | 665,147 | — | 8/6/2026 |
| Deep Track Biotechnology Master Fund, Ltd. | ▼ Sell | Other | 1,957,138 | — | 8/6/2026 |
| WALSH COLIN | ▼ Sell | Other | 1,957,134 | $0 | 8/6/2026 |
| venBio Global Strategic Fund IV, L.P. | ▼ Sell | Other | 821,998 | — | 8/6/2026 |
| WALSH COLIN | ▲ Buy | Open Market | 85,000 | $1.8M | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 988 | $22K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 447 | $10K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 1,332 | $29K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 200 | $4K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 1,556 | $34K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 3,402 | $75K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 480 | $10K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 100 | $2K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 753 | $17K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 672 | $15K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 6,970 | $154K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 1,163 | $26K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 100 | $2K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 6,763 | $146K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 76,418 | $1.6M | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 200 | $4K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 400 | $9K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 700 | $15K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 1,180 | $26K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 1,040 | $23K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 300 | $6K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 443 | $10K | 8/5/2026 |
| WALSH COLIN | ▼ Sell | Open Market | 200 | $4K | 8/5/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
ATTO shares dip as investors question valuation after cancer vaccine news
Attovia Therapeutics' stock moved lower as investors raised concerns about whether its current valuation is justified. The scrutiny comes as the broader oncology space sees attention, highlighted by recent discussion of Moderna's cancer vaccine development. The stock is trading near the lower end of its 52‑week range, with RSI indicating modest momentum.
ATTO shares dip as investors question valuation after cancer vaccine news. Attovia Therapeutics' stock moved lower as investors raised concerns about whether its current valuation is justified. The scrutiny comes as the broader oncology space sees attention, highlighted by recent discussion of Moderna's cancer vaccine development. The stock is trading near the lower end of its 52‑week range, with RSI indicating modest momentum.